Iveric's Zimura Succeeds In Dry AMD Study

Stock Sees Three-Day Gain Of 283%

The New York-headquartered  firm, which recently decided to focus on gene therapy, has to decide whether to partner Zimura or go it alone.

Eyes
The eyes have it for Iveric • Source: Shutterstock

Shares in Iveric Bio are continuing to soar after the small US biotech said its lead asset Zimura slowed eyesight deterioration in patients with dry age-related macular degeneration (AMD).

Top-line data from a Phase IIb trial of Zimura (avacincaptad pegol) showed that the complement C5 inhibitor reduced the rate...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Sensory

More from Therapeutic Category